Génome Québec is teaming with several industry partners to create a pharmacogenomics technology platform that will initially be used to detect the toxicity and efficacy of an investigational drug in an acute coronary syndrome trial, but is expected to have broader applicability for PGx-focused clinical trials.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.